STOCK TITAN

Marker Therapeutics (MRKR) Stock News

MRKR NASDAQ

Marker Therapeutics, Inc. reports developments as a clinical-stage immuno-oncology company developing non-genetically modified Multi-Antigen Recognizing T cell therapies for hematologic malignancies and solid tumor indications. Its recurring company updates center on the MAR-T cell platform, MT-601 in lymphoma, MT-401-OTS as an off-the-shelf program, and pancreatic cancer research connected to technology developed at Baylor College of Medicine.

Company news also covers clinical observations from named studies, non-dilutive funding from government and cancer-research programs, scientific publications and medical-meeting presentations, quarterly financial results, conference participation, shareholder voting matters, and board governance changes.

Rhea-AI Summary

Marker Therapeutics (MRKR) was awarded a $16.2 million grant from the Cancer Prevention and Research Institute of Texas. The non-dilutive funding will support the planned Phase 2 APOLLO study of MT-601 (neldaleucel), an investigational cell therapy for patients with relapsed or refractory large B-cell lymphoma after CD19-directed CAR-T therapy.

In August 2025, Marker reported a 66% objective response rate and a 50% complete response rate among 12 evaluable Phase 1 patients with non-Hodgkin lymphoma. Responses lasted up to 24 months at the data cutoff. No dose-limiting toxicities or immune effector cell-associated neurotoxicity syndrome were observed across the dose levels evaluated. Marker expects additional patient data and updated data on how long responses lasted later in 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
54.71%
Tags
-
Rhea-AI Summary

Marker Therapeutics (Nasdaq: MRKR) has been awarded a $2.6 million FDA grant to support development of MT-601 in pancreatic cancer. The non-dilutive funding will support a Phase 1 study in patients with locally advanced unresectable pancreatic cancer, meaning disease that cannot be surgically removed. Marker expects clinical initiation in the first quarter of 2027.

The program builds on a Baylor College of Medicine Phase 1/2 study of multi-antigen targeted T cells combined with frontline chemotherapy. That study reported an 84.6% disease control rate, median response duration of 7.5 months and median overall survival of 14.1 months. Marker described its safety profile as favorable. The planned company-sponsored study will incorporate broader antigen targeting, higher T cell doses and lymphodepletion, a treatment that reduces lymphocytes, with the aim of improving cell persistence and clinical outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.38%
Tags
none
-
Rhea-AI Summary

Marker Therapeutics (MRKR) outlined expanded manufacturing support for its lead cell therapy MT-601 (neldaleucel) following the formation of Kincellis Advanced Therapies from the combination of Cellipont Bioservices and Kincell Bio.

Kincellis is a U.S.-based CDMO focused on cell therapies, with approximately 140,000 square feet of development and manufacturing infrastructure and 16 operational, qualified GMP suites across three U.S. sites. Marker, which had already selected Cellipont as its MT-601 partner, expects the larger organization’s broader technical expertise, network and financial resources to better support MT-601 from ongoing clinical development toward potential pivotal-stage and commercial manufacturing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
none
Rhea-AI Summary

Marker Therapeutics (Nasdaq: MRKR) reported 2025 corporate and financial results on March 18, 2026. Key clinical highlights include a 66% objective response rate in relapsed non-Hodgkin lymphoma with 50% complete responses in the Phase 1 APOLLO update.

Other items: Nature Medicine pancreatic data showing up to 84.6% disease control, manufacturing collaboration with Cellipont, Board appointment of Kathryn Penkus Corzo, and year-end cash of $17 million (funding through Q4 2026 per the company). 2025 net loss was $12.2 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
-
Rhea-AI Summary

Marker Therapeutics (NASDAQ: MRKR) announced CEO Dr. Juan Vera will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, from 8:00–8:30 a.m. EST. The event is virtual; a webcast will be available via the company’s Investor Relations “Events and Presentations” page.

Management will hold one-on-one investor meetings to discuss progress across Marker’s Multi-Antigen Recognizing (MAR) T cell platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
none
-
Rhea-AI Summary

Marker Therapeutics (Nasdaq: MRKR) highlighted Baylor College of Medicine’s TACTOPS Phase 1/2 pancreatic cancer study on Good Morning America on Jan 22, 2026, and the research was recently published in Nature Medicine. The Baylor study reported a favorable safety profile and up to a 84.6% disease control rate in Arm A when Multi-Antigen Targeted T cells were combined with frontline chemotherapy. In Arm A the median duration of response was 7.5 months and median overall survival was 14.1 months; infused T cells were detected up to 12 months post-treatment. Marker plans a company-sponsored trial (NCT06549751) with expanded antigen targets, higher cell doses and lymphodepletion, has SBIR and CPRIT funding, and anticipates clinical initiation in H1 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.95%
Tags
none
Rhea-AI Summary

Marker Therapeutics (Nasdaq: MRKR) announced publication of Baylor College of Medicine clinical data showing a favorable safety profile and an 84.6% disease control rate in Arm A when Multi-Antigen Targeted T cells were combined with frontline chemotherapy in pancreatic ductal adenocarcinoma.

Key metrics: median duration of response 7.5 months (range 3.5–16.6) for responders and median overall survival 14.1 months. Infused T cells persisted at detectable levels 12 months post-treatment and higher frequencies correlated with clinical response. Marker says it plans to start its pancreatic program in H1 2026 and has secured non-dilutive NIH SBIR and CPRIT funding to support the program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.23%
Tags
none
-
Rhea-AI Summary

Marker Therapeutics (NASDAQ: MRKR) reported Q3 2025 results and program updates on Nov 14, 2025. Key clinical highlights include a 66% objective response rate and 50% complete response rate for MT-601 in relapsed NHL from the Phase 1 APOLLO study (8/12 ORR; 6/12 CR), with five responses ≥6 months and three ≥12 months. No DLTs or ICANS observed. The company treated the first patient in its Off-the-Shelf RAPID study and signed a cGMP manufacturing collaboration with Cellipont. Marker raised approximately $10.0 million via ATM; cash and restricted cash totaled $19.0 million at 9/30/25, funding operations into Q3 2026 under current assumptions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
-
Rhea-AI Summary

Marker Therapeutics (Nasdaq: MRKR) announced the appointment of Kathryn Penkus Corzo to its Board of Directors, effective November 1, 2025.

Ms. Penkus Corzo brings more than 30 years of biopharma leadership across R&D, clinical development, regulatory approvals, commercialization, and corporate strategy. She most recently served as President and COO at bit.bio and previously led oncology cell therapy development at Takeda Ventures, with senior roles at Sanofi Genzyme, Roche, Eli Lilly, and Syndax.

Company leadership said the appointment strengthens the board as Marker advances its lead asset MT-601 and the APOLLO program toward a potential pivotal study in patients with CAR-relapsed diffuse large B-cell lymphoma (DLBCL).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
management
Rhea-AI Summary

Marker Therapeutics (Nasdaq: MRKR) will present Phase 1 APOLLO data for MT-601 at the 67th ASH Annual Meeting, Dec 6-9, 2025 in Orlando.

Key results: in relapsed Non-Hodgkin lymphoma (NHL) patients ORR was 66% (8/12) with 50% CR; responses lasted 3–24 months with five patients ≥6 months and three >12 months. In Hodgkin lymphoma (HL) ORR was 78% (7/9) with 11% CR. No dose limiting toxicities or ICANS were reported; two participants had Grade 1 CRS. Company advanced to dose expansion at 400x10^6 cells in DLBCL post-CAR-T or CAR-T ineligible patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
conferences

FAQ

What is the current stock price of Marker Therapeutics (MRKR)?

Marker Therapeutics (MRKR) last closed at $1.09.

What is the market cap of Marker Therapeutics (MRKR)?

The market cap of Marker Therapeutics (MRKR) is approximately $18.2M.